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Over the past decade, services to pre-
vent mother-to-child transmission 
(PMTCT) of human immunodeficiency 
virus (HIV) have expanded rapidly, 
resulting in reductions in paediatric 
acquired immunodeficiency syndrome 
(AIDS) worldwide.1 However, although 
an emerging literature demonstrates 
high maternal HIV incidence during 
pregnancy and breastfeeding,2 efforts 
have not focused as much on preventing 
new infections among pregnant women 
or their partners. Although recent 
World Health Organization (WHO) 
recommendations for pre-exposure 
prophylaxis are encouraging,3 in sub-
Saharan Africa, few – if any – structured 
interventions are offered to women or 
their partners during pregnancy and 
breastfeeding. Most women who access 
PMTCT care test HIV-negative and for 
most, engagement in HIV prevention 
typically ends with individual post-test 
counselling. To address this gap, we 
describe a framework to guide HIV pre-
vention efforts for pregnant or breast-
feeding women and their partners. This 
approach considers the unique charac-
teristics of pregnancy, including health-
seeking behaviours of women and 
engagement of male partners, to stratify 
couples according to HIV transmission 
and acquisition risk. The approach also 
leverages the robust infrastructure of 
existing PMTCT programmes and in-
tegrates it within the broader context of 
general HIV prevention.
HIV incidence
Women in sub-Saharan Africa have 
a high risk of acquiring HIV during 
pregnancy and breastfeeding. In a 
meta-analysis of 19 studies from 1980 to 
2013 (cumulative 22 803 person-years), 
a pooled incidence rate of 4.7 per 100 
person-years (95% confidence interval, 
CI: 3.3–6.1) was reported during preg-
nancy and 2.9 per 100 person-years 
(95% CI: 1.8–4.0) while breastfeeding.2 
These rates are above WHO’s threshold 
for substantial population risk for HIV 
acquisition (3.0 per 100 person-years) 
and may be elevated compared to non-
pregnant women.
A new HIV infection has negative 
consequences for a woman’s survival 
and quality of life; it also has important 
implications for horizontal and verti-
cal HIV transmission. Pregnancy may 
increase the risk of HIV transmission 
from an HIV-infected woman to her 
HIV-uninfected male partner (adjusted 
hazard ratio: 2.47, 95% CI: 1.26–4.85).4 
Women who become acutely infected 
during pregnancy and breastfeeding 
have much higher rates of mother-to-
child HIV transmission, likely due to 
the high maternal viremia observed 
following new infections. As PMTCT 
services continue to expand, a growing 
proportion of overall vertical transmis-
sion, more than half in some analyses,5 
will be attributed to acute maternal HIV 
infection not identified by routine HIV 
antibody testing earlier in pregnancy.
HIV prevention
We propose a couples-based approach to 
HIV prevention that extends from an-
tenatal services. Under this framework, 
we use the HIV status of the pregnant 
woman and her partner to stratify 
our target population into six groups 
(Fig. 1). To optimally reduce horizontal 
HIV transmission during pregnancy 
and breastfeeding, a combination HIV 
prevention package must be individually 
tailored to each of these groups. When 
the HIV status of the partner is known, 
recommendations for HIV prevention 
are straightforward: an HIV-infected 
woman (groups B, D, E) or the HIV-
infected partner (groups C, D) should 
start lifelong antiretroviral therapy 
(ART). To maximize this prevention 
benefit, support is often needed to link 
these individuals to HIV care, ensure 
timely ART initiation and encourage 
long-term adherence. In many cases, the 
HIV status of the partner is unknown, as 
a proportion fail to access HIV testing 
despite strong programmatic efforts.6 
Given this group’s relative size and HIV 
risk, targeted interventions are needed 
for HIV-uninfected pregnant women 
with unknown partner HIV status 
(group F). Even when both partners 
initially test HIV-negative (group A), 
couples-based counselling and educa-
tion may be effective in reducing risk 
behaviours.
Our approach extends from sev-
eral published theoretical frameworks. 
Similar to the Awareness Framework,7 
knowledge and mutual disclosure of 
HIV status within the couple is a criti-
cal early step that guides HIV preven-
tion efforts. The transformation from 
person-centred motivation (that is, in-
dividual-based) to relationship-centred 
motivation (that is, couples-based) can 
lead to communal coping and coop-
erative action.8 In many circumstances, 
behaviour requires dyadic capacity for 
coordinated action and this can be in-
fluenced at the interpersonal, individual 
and structural levels.9
Several aspects of pregnancy are 
well suited for HIV prevention efforts. 
The heightened risk for incident HIV 
appears concentrated in pregnancy 
and breastfeeding, suggesting that 
time-limited interventions may be ef-
fective. In many African settings, even 
rural ones, there exists a tradition of 
institutional health care during this 
period.10Altruistic motivations towards 
the unborn infant are well documented 
among expectant mothers11,12 and this 
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can drive health-seeking behaviours that 
endure beyond pregnancy and breast-
feeding. Growing evidence suggests that 
greater male partner engagement is also 
possible and can lead to improved health 
outcomes.
Opportunities for HIV 
prevention
We highlight potential opportunities 
for HIV prevention using our couples-
based framework during pregnancy and 
breastfeeding. First, expanded efforts are 
needed to increase partner HIV testing 
(Fig. 1, intervention 1). Male partner 
involvement has been long-promoted 
in antenatal settings, but the nature of 
effective engagement has not been well 
defined. As a result, while antenatal 
HIV testing is near universal in most 
African settings, uptake by the male 
partners of pregnant women has lagged. 
In a systematic review of 15 studies, 
the percentage of male partners who 
routinely agreed to HIV testing (that 
is, within the standard of care) was be-
low 25% in most programmes.6 Newer 
strategies emphasize male partner HIV 
testing in convenient and supportive 
environments, including voluntary part-
ner notification, home-based couples 
testing, secondary distribution of HIV 
self-test kits and others. Although many 
of these approaches are recommended 
by WHO, a single strategy will probably 
not be sufficient to increase partner HIV 
testing to the reach the 90–90–90 targets 
set forth by the Joint United Nations 
Programme for HIV/AIDS, that is, by 
2020, 90% of all HIV-infected indi-
viduals know their status; 90% of those 
diagnosed with HIV receive ART; and 
90% of those on ART achieve viral sup-
pression.13 Tailored approaches, includ-
ing choice-based strategies that solicit 
individual patient preferences, should be 
considered alongside interventions that 
facilitate communication and strengthen 
relationships between partners.
Second, linkages to other health 
services are needed. Significant attrition 
is observed early in the HIV treatment 
cascade, both for HIV-infected pregnant 
women and their partners. Couples-
based approaches may have greater 
impact on linkages to and retention in 
HIV care than those focusing on preg-
nant women alone (Fig. 1, intervention 
2, groups B–E).8,9 In addition, women 
who are newly diagnosed with HIV, 
and newly initiating ART, may require 
more intensive support compared with 
those who have been stable on long-term 
HIV treatment. Such strategies could 
also hold promise for HIV-uninfected 
partners. For male partners who test 
HIV-negative (Fig. 1, groups A, B), facil-
itated linkages to other HIV prevention 
services (for example, risk-reduction 
counselling, male circumcision and 
pre-exposure prophylaxis) could lead 
Fig. 1. Proposed couples-based framework for HIV prevention for pregnant or breastfeeding women and their partners
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ART: antiretroviral therapy; HIV: human immunodeficiency virus; PreP: pre-exposure prophylaxis
Notes: Based on results of HIV testing for both members, couples are categorized into one of six groups (A–F) according to the status of the pregnant or 
breastfeeding women (HIV-infected or -uninfected) and her partner (HIV-infected, -uninfected or -unknown). We also highlight potential opportunities for HIV 
prevention through evidence-based practices (interventions 1–3).
to reductions in HIV incidence in this 
population.
Third, even with an increased focus 
on couples-based HIV testing, a signifi-
cant proportion of pregnant or breast-
feeding women will still not know the 
HIV status of their partners. A partner’s 
unknown HIV status, particularly in 
the setting of accessible testing services, 
represents an important risk factor for 
incident HIV infection.14 Given the rela-
tive size of this group, novel strategies 
are needed to ensure effective preven-
tion for these HIV-uninfected women. 
Oral pre-exposure prophylaxis may be a 
promising strategy for HIV-uninfected 
women with unknown partner HIV sta-
tus (Fig. 1, intervention 3, group F).3 The 
safety profile of tenofovir–emtricitabine 
is favourable and the intervention is 
cost–effective during pregnancy across 
a range of model assumptions.15 This 
intervention is also important for HIV-
uninfected women in known serodis-
cordant couples (Fig. 1, intervention 3, 
group C), even when their male partner 
initiates ART, given the time needed to 
achieve virologic suppression and chal-
lenges with male HIV care-seeking and 
adherence.16
Fourth, the couples-based approach 
is not restricted to a pregnant woman’s 
primary partner; it can be used to evalu-
ate her risk from secondary partners and 
guide prevention efforts accordingly. 
This framework, however, may not fully 
delineate the sexual network of the male 
partner, which can be an important 
predictor of HIV risk. In the HIV Pre-
vention Trials Network (HPTN) 052 
study, the multi-country randomized 
trial that established the high efficacy 
of treatment for prevention, only 67% 
(52/78) of incident HIV infections could 
be genetically linked to the primary 
partner.17 The role of sexual networks 
in HIV transmission deserves further 
study in this context, from the perspec-
tives of the pregnant or breastfeeding 
woman and her partner(s).
Finally, approaches are needed to 
better integrate pregnant or breastfeed-
ing populations within HIV prevention 
research. Efficacy trials often exclude 
women who are pregnant at time 
of enrolment; given the significant 
physiological changes associated with 
pregnancy and its potential impact on 
drug absorption and metabolism, this 
may create delays in the adoption of 
otherwise efficacious interventions dur-
ing this high-risk period. The exclusion 
of pregnant and breastfeeding women 
from efficacy trials may also negatively 
affect the availability of promising future 
interventions, including antiretroviral 
delivery systems, long-acting agents and 
therapeutic modalities. While the con-
duct of research in pregnant women can 
be ethically challenging and complex, 
the success of efforts a round P MTCT 
show how it can be accomplished 
within current ethical and 
regulatory frameworks. 
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